23/04/2026
Maxima Biotech Unveils "MedTech Foundry" Strategy: Delivering Customized Innovation and Supply Chain Resilience for Global MedTech Leaders
[Taipei, Taiwan – April 23, 2026] – In a global landscape shifting toward supply chain resilience and localized autonomy, Maxima Biotech is emerging as a critical "Resilience Anchor" for the medical device industry. By pioneering the "MedTech Foundry" model, Maxima offers multinational corporations (MNCs) a high-efficiency platform for customized technology integration and rapid commercialization, transitioning the paradigm from "Made in Taiwan" to "Enabled by Taiwan".
Realizing the "MedTech Foundry" with IRCAD and Qisda
The strategic evolution was recently highlighted during a high-level visit by Antonello Forgione, General Manager of IRCAD, and his team to the Qisda Medical Fleet. Prof. Forgione offered his congratulations on Taiwan’s milestones—achieving a 10% domestic market share and completing over 6,000 documented surgeries within just three years.
Reflecting on the industry’s progress, Prof. Forgione noted that while 40 years have passed since the dawn of Minimally Invasive Surgery (MIS), surgeons are incredibly still using hot water to clean the lens. He encouraged the team to stay laser-focused on real, clinical unmet needs rather than falling into the "capital game," reaffirming that true leadership stems from practical innovations that directly benefit patients.
Customized Innovation and Strategic IP Defense
Dr. Tom Tang, CEO of Maxima Biotech, detailed the company’s strategic B2B positioning: "Our goal is to serve as an 'Innovation Engine' for global leaders with validated market intelligence. We provide MNCs with highly customizable technology options—such as our advanced cordless ultrasonic and bipolar platforms—allowing partners to rapidly deploy 'fighting brands' and upgrade portfolios without the prohibitive costs of new infrastructure".
Through "In Situ Innovation," Maxima leverages Taiwan’s "1-Hour Cluster" to reduce traditional 10-year commercialization cycles to just 3 years. This is backed by a 5-year strategic partnership with Worcester Polytechnic Institute (WPI), which provides rigorous Patent Landscape Mapping and clear Freedom to Operate (FTO) for Maxima’s global partners.
Looking Ahead: Integrating with IRCAD’s Global Network for Advanced Healthcare
To further catalyze these international alliances, Maxima Biotech proposes organizing a Taiwan delegation to IRCAD’s headquarter for direct dialogues with global MNC executives. Simultaneously, IRCAD will begin planning to integrate Taiwan’s unique precision manufacturing and R&D capabilities into IRCAD’s extensive global medical network and its associated multinational partners.
This mission is deeply rooted in the "International Alliance" core framework of President Lai Ching-te's "National Medical Supplies Resilience Preparedness Plan". By leveraging the unmatched efficiency and quality of Taiwan’s "MedTech Foundry" model, Maxima Biotech aims to break traditional price monopolies of high-end equipment, ensuring that patients worldwide can access advanced, precise healthcare at a reasonable cost, ultimately realizing true healthcare democratization and equity.
賴清德
『非佳不可』Qisda 佳世達科技
IRCAD
Worcester Polytechnic Institute (WPI)
#國家藥物韌性整備計畫
Ircad Taiwan 秀傳亞洲遠距微創手術中心
